Cytokinetics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
The current Cytokinetics(CYTK) stock price is $65.95, with a market capitalization of 7.99B. The stock trades at a price-to-earnings (P/E) ratio of -10.37.
On 2025-11-21, Cytokinetics(CYTK) stock traded between a low of $63.02 and a high of $66.76. Shares are currently priced at $65.95, which is +4.6% above the low and -1.2% below the high.
Cytokinetics(CYTK) shares are trading with a volume of 1.41M, against a daily average of 2.05M.
During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $67.98 at its peak.
During the past year, Cytokinetics(CYTK) stock moved between $29.31 at its lowest and $67.98 at its peak.
CYTK News
In recent days, Cytokinetics announced additional positive clinical trial data for aficamten in hypertrophic cardiomyopathy, with results showing significant im...
Several law firms have recently filed securities class action lawsuits and launched investigations into Cytokinetics (CYTK), claiming that the company misled in...
New insider activity at Cytokinetics ( (CYTK) ) has taken place on November 18, 2025. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help yo...
Analyst ratings
81%
of 21 ratingsMore CYTK News
Cytokinetics (CYTK) announced its support of a three-year initiative led by the American Heart Association, AHA, to address disparities in access to care, diagn...